Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Nuwiq

    - PMLiVE

    Roche’s Columvi improves survival in large B-cell lymphoma

    Approximately 160,000 people are diagnosed with this aggressive form of cancer each year

    - PMLiVE

    Roche receives FDA clearance for whooping cough test

    There are around 24.1 million cases of whooping cough annually, with around 170,000 deaths

    - PMLiVE

    Genentech announces positive clinical results for BTK inhibitor MS treatment

    Multiple sclerosis affects more than 2.9 million people globally

    - PMLiVE

    Roche’s small cell lung cancer therapy approved by FDA

    This is the first and only approved combination therapy for extensive-stage small cell lung cancer

    - PMLiVE

    Roche’s Lunsumio receives positive CHMP opinion for follicular lymphoma

    The recommendation for the subcutaneous formulation follows encouraging trial data

    - PMLiVE

    EMA reaffirms guidance on paracetamol use during pregnancy

    The guidance follows recent US comments about a possible link to autism

    - PMLiVE

    Roche to acquire 89bio in a deal worth up to US$3.5bn

    With the agreement, Roche will gain a treatment for moderate to severe MASH

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    Genentech starts construction on manufacturing facility in North Carolina, US

    The $700m project is part of Roche’s $50bn investment in the US

    - PMLiVE

    EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

    This follows preliminary results from the company's ongoing phase 2 trial

    - PMLiVE

    FDA approves PTC Therapeutics’ Sephience to treat rare metabolic disorder PKU

    Phenylketonuria affects one in every 13,500 to 19,000 newborns in the US

    - PMLiVE

    Roche’s Evrysdi tablets approved by MHRA to treat spinal muscular atrophy

    It is hoped the new formulation will offer patients greater freedom and flexibility compared to the liquid version

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links